Plain-English translation of NCT06086457 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing a new treatment approach for advanced esophageal cancer that has spread to other organs. You would receive Camrelizumab (an immune-boosting medication) combined with chemotherapy, and some patients would also receive targeted radiation therapy to help kill cancer cells. The goal is to see whether adding radiation to this combination treatment helps people live longer and feel better.
For decades, chemotherapy alone has been the standard treatment for advanced esophageal cancer, but it hasn't improved survival much. Recent studies show that adding immune therapy to chemotherapy works better, but doctors still need to know whether adding radiation therapy on top of that combination would help even more.
You likely qualify if…
You likely don't qualify if…
You would be randomly assigned to receive either chemotherapy plus immune therapy alone, or the same treatment plus radiation therapy sessions. Chemotherapy would be given over about 6 cycles, and if you're in the radiation group, you'd receive radiation therapy between your first and third chemotherapy cycles. Throughout the trial, you'd have regular doctor visits, blood tests, and scans to monitor how you're responding, and researchers would also collect blood and tissue samples to study what helps predict who benefits most from this treatment.
AI-generated summary from trial data · Jul 21, 2026 · Not medical advice
China